Orotic acid (Acidum oroticum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Anabolics

Included in the formulation
  • Potassium orotate
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Potassium orotate
    pills inwards 
    AVVA RUS, OJSC     Russia
  • Potassium orotate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Potassium orotate
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Potassium orotate
    pills inwards 
    PHARMSTANDART-TOMSKHIMFARM, OJSC     Russia
  • Potassium orotate tablets 0.5 g
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
    • АТХ:

    A.12.C.X   Preparations of other minerals

    Pharmacodynamics:

    Orotic acid is one of the precursors pyrimidine nucleotides that are part of the nucleic acids involved in the formation of protein molecules, in connection with which the salts of orotic acid are considered as substances of anabolic action and are used in the violation of protein metabolism, for their stimulation.

    The drug enhances regenerative and reparative tissue processes, the formation of albumin in the liver (especially in hypoxic conditions), increases diuresis, and increases appetite.

    Pharmacokinetics:

    Absorbed in the gastrointestinal tract (10%), metabolized in the liver to orotidin-5-phosphate, excreted by the kidneys.

    Indications:

    In the combination therapy:

    Diseases of the liver and biliary tract, which are caused by intoxication (except for cirrhosis with ascites).

    Dermatosiss.

    Heart rhythm disturbances (especially with extrasystole and atrial fibrillation).

    Myocardial infarction and chronic heart failure II and III stage.

    Progressive muscular dystrophy.

    Alimentary / alimentary-infective hypotrophy in children.

    Increased physical activity.

    Period of convalescence.

    ICD-10

    I.B15-B19.B19   Viral hepatitis, unspecified

    III.D60-D64.D64   Other anemia

    III.D60-D64.D64.9   Anemia, unspecified

    IV.E40-E46.E46   Protein-energy insufficiency, unspecified

    IV.E50-E64.E63   Other types of malnutrition

    IV.E70-E90.E78.5   Hyperlipidemia, unspecified

    VI.G70-G73.G71.0   Muscular dystrophy

    IX.I20-I25.I20   Angina pectoris [angina pectoris]

    IX.I20-I25.I21   Acute myocardial infarction

    IX.I30-I52.I42   Cardiomyopathy

    IX.I30-I52.I49.4   Other and unspecified depolarization

    IX.I30-I52.I49.8   Other specified disorders of heart rhythm

    IX.I30-I52.I50.0   Congestive heart failure

    IX.I30-I52.I51.5   Degeneration of the myocardium

    IX.I70-I79.I70   Atherosclerosis

    IX.I70-I79.I73.9   Peripheral vascular disease, unspecified

    XI.K70-K77.K71   Toxic liver disease

    XI.K70-K77.K73   Chronic hepatitis, not elsewhere classified

    XI.K70-K77.K76.9   Liver disease, unspecified

    XI.K80-K87.K83.9   Disease of biliary tract, unspecified

    XII.L20-L30.L20.8   Other atopic dermatitis

    XII.L20-L30.L30.9   Dermatitis, unspecified

    XVI.P90-P96.P92.3   Undernutrition of the newborn

    XVIII.R50-R69.R53   Malaise and fatigue

    XXI.Z40-Z54.Z54   Condition of recovery

    XXI.Z70-Z76.Z73.3   Stress condition, not elsewhere classified

    Contraindications:

    Nephrourolithiasis.

    Cirrhosis of the liver with ascites.

    Acute and chronic liver disease.

    Hypersensitivity.

    Carefully:

    Pregnancy and lactation.

    Pregnancy and lactation:

    Category FDA not determined. With caution in pregnancy and lactation.

    Dosing and Administration:

    Orally: 250-500 mg 2-3 times a day for 1 hour before meals or 4 hours after meals. The course of treatment is 20-40 days, a second course is possible in a month.

    Children: 10-20 mg / kg per day for 2-3 admission, treatment course 3-5 weeks.

    Side effects:

    Dispecial phenomena (nausea, vomiting).

    Liver dystrophy.

    Allergic dermatosis.

    Overdose:

    Not described, treatment is symptomatic.

    Interaction:

    Admission simultaneously with GCS, diuretics, insulin, oral contraceptives, muscle relaxants reduces the effectiveness of the drug.

    The drug disrupts the absorption of tetracycline, iron, sodium fluoride.

    The drug reduces the toxicity of cardiac glycosides, the effect is enhanced when it is combined with magnesium preparations.

    Astringent and enveloping agents can somewhat reduce the absorption of orotic acid in the gastrointestinal tract.

    Special instructions:

    During the treatment period is desirable dieting.

    Impact on the ability to drive vehicles and manage mechanisms

    It is not revealed (does not cause drowsiness and decrease in the speed of psychomotor reactions).

    Instructions
    Up